Search Results - "Brenton, J.D"

Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging by Sala, E, Mema, E, Himoto, Y, Veeraraghavan, H, Brenton, J.D, Snyder, A, Weigelt, B, Vargas, H.A

“…Tumour heterogeneity in cancers has been observed at the histological and genetic levels, and increased levels of intra-tumour genetic heterogeneity have been…”
Get full text

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial by Piskorz, A.M, Lin, K.K, Morris, J, Mann, E, Oza, A, Coleman, R.L, O'Malley, D.M, Friedlander, M, Cragun, J.M, Ma, L, Giordano, H, Raponi, M, McNeish, I.A, Swisher, E, Brenton, J.D

“…Background: TP53 mutations are present in >97% cases of high-grade serous ovarian cancer (HGSOC). Detection of TP53 mutations in ctDNA extracted from plasma…”
Get full text

28MO Real-world whole sequencing data of ovarian cancer patients by Funingana, I.G., Ambrose, J., Hosking, K., Demiris, N., Sosinsky, A., Brenton, J.D.

Get full text

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer by Vergote, I., González-Martín, A., Ray-Coquard, I., Harter, P., Colombo, N., Pujol, P., Lorusso, D., Mirza, M.R., Brasiuniene, B., Brenton, J.D., Ausems, M.G.E.M., Büttner, R., Lambrechts, D., Vergote, I., Ausems, M., Brasiuniene, B., Brenton, J., Büttner, R., Colombo, N., González-Martín, A., Harter, P., Lambrechts, D., Lorusso, D., Madry, R., Mirza, M.R., Pujol, P., Ray-Coquard, I., Abreu, M., Balboni, S., Banerjee, S., Barberis, M., Barretina Ginesta, M.P., Baurain, J.-F., Bignami, M., Blecharz, P., Bruchim, I., Capilna, M., Cerana, N., Cicchetti, A., Collins, D., Concin, N., D’Incalci, M., de la Motte Rouge, T., De Iaco, P., Denys, H., Doerk, T., Dorum, A., Fidalgo, A.P., Genuardi, M., Gladieff, L., Glasspool, R., Grimm, C., Gultekin, M., Hahnen, E., Hasenburg, A., Hegmane, A., Hogdall, E., Janavicius, R., Jarmalaite, S., Kalachand, R., Kaneva, R., Kilickap, S., Kocian, R., Kolencik, D., Kristeleit, R., Kryzhanivska, A., Leary, A., Lemley, B., Ligtenberg, M., Lord, C.J., Avall-Lundqvist, E., Maenpaa, J., Mahner, S., Marmé, F., Marth, C., McNeish, I., Merkelbach-Bruse, S., Mourits, M., Normanno, N., Oaknin, A., Papdimitriou, C., Penault-Llorca, F., Perrone, A.M., Pignata, S., Pikarsky, E., Rouleau, E., Rubio, M., Schmalfeldt, B., Sehouli, J., Shapira, R., Steffensen, K.D., Sukhin, V., Syrios, J., Szallasi, Z., Taskiran, C., Terzic, M., Tischkowitz, M., Toth, I., Wimberger, P., Witteveen, E.

“…Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of…”
Get full text

Prognostic gene expression signature for high-grade serous ovarian cancer by Intermaggio, M.P., Leong, H.S., Chen, S., Elatre, W., Gilks, B., Volchek, M., Wang, C., Mackenzie, R., George, J., Bowtell, D., Chenevix-Trench, G., Green, A., Gertig, D., Fereday, S., Moore, S., Hung, J., Harrap, K., Malt, M., Robertson, R., Maidens, J., Jayde, V., Mamers, P., Schmidt, T., Ball, C., Bilic, Sanela, Stuart-Harris, R., Clingan, P., Glasgow, A., Shannon, J., Young, B., Robertson, G., Carter, J., Dalrymple, C., Russell, P., Links, M., Jaworski, R., Crandon, A., Horwood, K., Obermair, A., Wyld, D., Davy, M., Dodd, T., Healy, T., Pittman, K., Henderson, D., Pierdes, J., Brown, B., Hyde, S., Healy, D., McNealage, J., Simpson, I., Fox, S., Lade, S., Loughrey, M., Neesham, D., Bell, R., Ng, L.F., Whiteman, D., Fereday, S., Steed, H., Koziak, J.M., Goranova, T., Silva De Silva, D., Ramón y Cajal, T., García-Donas, J., Rodriguez, G.C., Harris, H.R., Greene, C.S., Zelaya, R.A., Sinn, P., Menkiszak, J., Pearce, C.L., Rhenius, V., Piskorz, A.M., Sharma, R., Johnatty, S.E., Larson, M.C., Luk, H., Hernandez, B.Y., Thompson, P.J., Sherman, M.E., Bodelon, C., Lewsley, L.A., Banerjee, S.N., Stronach, E.A., Haluska, P., Ray-Coquard, I., Winterhoff, B., Slamon, D., Levine, D.A., Menon, U., Goodman, M.T., Schildkraut, J.M., Brown, R., Berchuck, A., Chenevix-Trench, G., deFazio, A., Beeghly-Fadiel, A., Fasching, P.A., Orsulic, S.

“…Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no…”
Get full text

Circulating tumour DNA for clinicians: current and future clinical applications by Thompson, M.K., Gale, D., Brenton, J.D.

“…This review introduces clinicians to the basic concepts of the biology of circulating tumour DNA (ctDNA), which is required to understand clinical use of ctDNA…”
Get full text

575P Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade serous or endometrioid ovarian cancer: A multi-national observational study by Morgan, R.D., Clamp, A.R., Barnes, B., Schlecht, H., Yarram-Smith, L., Wallis, Y., Morgan, S., Valganon, M., Hudson, E., McKenna, S., Sundar, S., Nicum, S., Brenton, J.D., Kristeleit, R., Banerjee, S., McNeish, I., Ledermann, J.A., Taylor, S., Evans, G., Jayson, G.C.

Get full text

33P The development of infrastructure for mainstream ovarian cancer genetic testing (DEMO) by Funingana, I.G., Leung, E., Alcaraz, M-L., Bird, L., Ang, J.E., Parkinson, C., Jimenez-Linan, M., Freeman, S., Spencer, C., Winning, J., Ganesan, R., Williams, S., Ong, K.R., Abedin, P., Sundar, S., Balega, J., Brenton, J.D.

Get full text

Personalising Treatment for High-Grade Serous Ovarian Carcinoma by Cojocaru, E., Parkinson, C.A., Brenton, J.D.

“…Ovarian cancer is a heterogeneous group of cancers that differ by cell of origin and genomic features. High-grade serous ovarian cancer (HGSOC) is the…”
Get full text

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial by Ali, H.R., Dariush, A., Thomas, J., Provenzano, E., Dunn, J., Hiller, L., Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J.M.S., Cameron, D.A., Hayward, L., Brenton, J.D., Pharoah, P.D.P., Irwin, M.J., Walton, N.A., Earl, H.M., Caldas, C.

“…We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer…”
Get full text

805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment by Clamp, A.R., James, E.C., McNeish, I., Dean, A., Kim, J-W., O'Donnell, D.M., Hook, J., Gallardo-Rincon, D., Coyle, C., Blagden, S., Brenton, J.D., Naik, R., Perren, T.J., Sundar, S., Cook, A., Badrock, J., Swart, A.M., Parmar, M.K., Kaplan, R.S., Ledermann, J.A.

Get full text

Population exposure-safety and exposure-efficacy analyses for rucaparib in patients (pts) with recurrent ovarian carcinoma (rOC) from Study 10 and ARIEL2 by Konecny, G.E., Oza, A.M., Tinker, A.V., Oaknin, A., Shapira-Frommer, R., Ray-Coquard, I., Aghajanian, C., Coleman, R.L., O'Malley, D.M., Leary, A., Chen, L.M., Provencher, D., Ma, L., Brenton, J.D., Castro, C.M., Green, M., Simmons, A.D., Beltman, J., Harding, T., Goble, S., Maloney, L., Kristeleit, R., McNeish, I.A., Swisher, E.M., Xiao, J.J.

Get full text

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma by Cooke, S L, Ng, C K Y, Melnyk, N, Garcia, M J, Hardcastle, T, Temple, J, Langdon, S, Huntsman, D, Brenton, J D

“…Resistance to chemotherapy in ovarian cancer is poorly understood. Evolutionary models of cancer predict that, following treatment, resistance emerges either…”
Get full text

Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples by Piskorz, A.M., Ennis, D., Macintyre, G., Goranova, T.E., Eldridge, M., Segui-Gracia, N., Valganon, M., Hoyle, A., Orange, C., Moore, L., Jimenez-Linan, M., Millan, D., McNeish, I.A., Brenton, J.D.

“…Next-generation sequencing (NGS) of tumour samples is a critical component of personalised cancer treatment, but it requires high-quality DNA samples. Routine…”
Get full text

7P Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC): A single-centre prospective experience by Funingana, I.G., Trotman, J., Ambrose, J., Roberts, T., Watkins, J., Ridley, M., Gilson, B., Freeman, S., Jimenez-Linan, M., Sosinsky, A.A., Tadross, J., Tarpey, P., Brenton, J.D.

Get full text

PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) by Basu, B., Gourley, C., Gabra, H., Vergote, I.B., Brenton, J.D., Abrahmsen, L., Smith, A., Von Euler, M., Green, J.A.

Get full text

373 - Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial by Piskorz, A.M., Lin, K.K., Morris, J., Mann, E., Oza, A., Coleman, R.L., O'Malley, D.M., Friedlander, M., Cragun, J.M., Ma, L., Giordano, H., Raponi, M., McNeish, I.A., Swisher, E., Brenton, J.D.

Get full text

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment by Clamp, A.R., McNeish, I.A., Dean, A., Gallardo-Rincon, D., Kim, J.-W., O’Donnell, D.M., Hook, J., Blagden, S., Brenton, J.D., Naik, R., Perren, T.J., Sundar, S., Cook, A.D., James, E.C., Gabra, H., Lord, R., Hall, M., Dark, G., Kaplan, R.S., Ledermann, J.A.

Get full text

Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium by Archibald, K M, Kulbe, H, Kwong, J, Chakravarty, P, Temple, J, Chaplin, T, Flak, M B, McNeish, I A, Deen, S, Brenton, J D, Young, B D, Balkwill, F

“…Early genetic events in the development of high-grade serous ovarian cancer (HGSOC) may define the molecular basis of the profound structural and numerical…”
Get full text

255 Correlating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with changes in tumour volume, as a predictor of radiation response in cervix cancer by Zahra, M.A., Hollingsworth, K.G., Sala, E., Lomasz, D.J., Brenton, J.D., Arends, M.J., Crawford, R.A.F., Tans, L.T.

Get full text